Amrutanjan Health Care Limited (AMRUTANJAN) AI Stock Analysis

• Market Cap: ₹18.34B
• Dividend Yield: 0.68%
• Average Volume (3M): 587.00
• Price to Earnings (P/E): 32.0
• Beta (1Y): 1.01
• Revenue Growth: 7.36%
• EPS Growth: 19.31%
• Country: IN
• Employees: 634
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 4.83
• Shares Outstanding: 29,230,630
• 10 Day Avg. Volume: 607
• 30 Day Avg. Volume: 587
• PEG Ratio: 2.73
• Price to Book (P/B): 5.70
• Price to Sales (P/S): 4.13
• P/FCF Ratio: 121.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 72 Outperform
• Price Target: ₹798.00 ▲(18.84% Upside)

Amrutanjan Health Care Limited scores well due to its strong financial performance, characterized by consistent revenue and profit growth, and a solid balance sheet. The technical analysis suggests a neutral to slightly bearish outlook, while the valuation indicates the stock is fairly priced. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates expanding market reach and product adoption, enhancing long-term financial stability.

Balance Sheet Health

A strong balance sheet with low leverage enhances financial flexibility and reduces risk, supporting sustainable growth.

Cash Flow Management

Effective cash flow management ensures liquidity and supports reinvestment in growth opportunities, bolstering long-term prospects.

Negative Factors

EBITDA Margin Fluctuations

Variability in margins suggests challenges in cost management, which could impact profitability and operational efficiency.

Free Cash Flow Volatility

Volatility in free cash flow may affect the company's ability to fund operations and investments, posing a risk to financial stability.

Operational Efficiency

Inefficiencies in operations can lead to increased costs and reduced margins, impacting long-term competitiveness and profitability.

Amrutanjan Health Care Limited Business Overview & Revenue Model

Company Description

Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms, non-alcoholic beverages, and sanitary napkins. The company operates through OTC Products, Beverages, and Others segments. It provides pain management products comprising pain balms and roll-ons; and back pain roll-ons and lotions, body pain gels, and joint muscle sprays, as well as diclofenac, a non-steroidal anti-inflammatory drug. The company offers congestion management products that consists of cold rubs, cough syrups, nasal inhalers, and swas mints. It also provides sanitary napkins for women. In addition, the company offers corn caps; hand sanitizers; and juice drinks under the Fruitnik and Fruitnik Electro+ brand names, as well as operates a pain management center. It exports its products to the Middle East, Africa, South East Asia, and internationally. The company was formerly known as Amrutanjan Limited and changed its name to Amrutanjan Health Care Limited in 2007. Amrutanjan Health Care Limited was founded in 1893 and is based in Chennai, India.

How the Company Makes Money

Amrutanjan generates revenue primarily through the sale of its wide array of healthcare products, including pain relief ointments, balms, and other wellness items. The company's revenue model is centered around direct consumer sales, distribution through pharmacies, and partnerships with retail chains. Key revenue streams include both domestic sales and exports, with a growing focus on e-commerce channels to reach a broader audience. Significant partnerships with retail distributors and health-focused online platforms enhance the company's market reach and contribute to its earnings. Additionally, Amrutanjan invests in marketing and brand promotion to strengthen its position in the competitive healthcare market, driving consumer awareness and sales growth.

Amrutanjan Health Care Limited Financial Statement Overview

Summary

Amrutanjan Health Care Limited demonstrates strong financial health with consistent revenue and profit growth, solid balance sheet management, and healthy cash flows. While the company shows strong profitability and liquidity, the variability in certain operational metrics indicates areas for improvement in efficiency and cost control.

Income Statement

Amrutanjan Health Care Limited shows a solid performance with steady revenue growth, increasing from 2020 to 2025. Gross and net profit margins are healthy, indicating strong profitability. However, fluctuations in EBIT and EBITDA margins over the years suggest some cost management challenges.

Balance Sheet

The company maintains a strong balance sheet with a low debt-to-equity ratio, indicating prudent leverage management. Consistent growth in stockholders' equity and a robust equity ratio underpin financial stability. The cash reserves are substantial, enhancing liquidity.

Cash Flow

Cash flow analysis reveals a positive trend in operating cash flow and effective capital expenditure management. However, free cash flow growth has been inconsistent, suggesting potential volatility in cash generation. The company maintains a healthy operating cash flow to net income ratio, indicating efficient cash conversion.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.62B	4.51B	4.21B	3.80B	4.05B	3.32B
Gross Profit	2.38B	2.46B	1.46B	1.98B	2.25B	1.91B
EBITDA	807.63M	758.79M	681.60M	590.79M	946.99M	861.66M
Net Income	545.30M	508.35M	449.73M	398.35M	671.89M	611.90M
Balance Sheet
Total Assets	0.00	4.21B	3.67B	3.62B	3.50B	2.74B
Cash, Cash Equivalents and Short-Term Investments	1.99B	1.95B	2.07B	1.93B	2.01B	1.75B
Total Debt	0.00	20.78M	17.28M	9.09M	8.80M	13.42M
Total Liabilities	-3.27B	947.73M	783.82M	713.21M	847.44M	587.06M
Stockholders Equity	3.27B	3.27B	2.88B	2.91B	2.65B	2.16B
Cash Flow
Free Cash Flow	0.00	153.46M	211.93M	102.91M	287.32M	878.02M
Operating Cash Flow	0.00	508.99M	279.11M	192.18M	521.96M	897.63M
Investing Cash Flow	0.00	-309.66M	191.65M	-24.75M	-362.12M	-877.61M
Financing Cash Flow	0.00	-134.90M	-482.66M	-140.26M	-167.02M	-62.83M

Amrutanjan Health Care Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 671.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AMRUTANJAN, the sentiment is Negative. The current price of 671.5 is above the 20-day moving average (MA) of 662.37, below the 50-day MA of 677.80, and below the 200-day MA of 695.61, indicating a bearish trend. The MACD of -15.96 indicates Positive momentum. The RSI at 28.00 is Positive, neither overbought nor oversold. The STOCH value of 19.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:AMRUTANJAN.

Amrutanjan Health Care Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMRUTANJAN	72 Outperform	₹18.34B	31.98	―	0.68%	7.36%	19.31%
TTKHLTCARE	71 Outperform	₹14.22B	21.46	―	0.95%	6.98%	-17.11%
KRSNAA	62 Neutral	₹23.70B	27.95	―	0.38%	11.51%	21.56%
ZOTA	52 Neutral	₹43.51B	-63.38	―	0.06%	82.58%	-63.05%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INDOCO	40 Neutral	₹20.18B	-17.93	―	0.08%	-2.81%	-444.69%

Amrutanjan Health Care Limited Corporate Events

Amrutanjan Closes Trading Window Ahead of December Quarter Results

Amrutanjan Health Care Limited has announced the closure of its trading window for designated persons from January 1, 2026 until 48 hours after the declaration of its unaudited financial results for the quarter ending December 31, 2025, in line with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company’s internal Code of Conduct. The move is a routine compliance measure aimed at preventing insider trading and ensuring that directors, employees and other designated insiders do not trade in the company’s securities while in possession of potentially price-sensitive financial information, thereby reinforcing governance standards and safeguarding stakeholder interests ahead of the quarterly results announcement.